Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$25.24 USD

25.24
18,327,111

-0.21 (-0.83%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $25.29 +0.05 (0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (101 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Ekta Bagri headshot

Biotech Stock Roundup: MRNA's Vaccine Update, GILD's CAR T Therapy Label Expansion

by Ekta Bagri

Regulatory and pipeline updates from bigwigs like Moderna (MRNA) and Gilead (GILD) have been the biotech sector's few key highlights during the past week.

Zacks Equity Research

Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $332.11, marking a +1.92% move from the previous day.

Zacks Equity Research

Why Moderna (MRNA) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Moderna (MRNA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Here's Why You Should Retain Myriad Genetics (MYGN) for Now

by Zacks Equity Research

Investors are optimistic about Myriad Genetics (MYGN) owing to strong testing volume growth and notable product launches.

Daniel Laboe headshot

Market Bears Take The Bulls By The Horns As Q4 Kicks Off

by Daniel Laboe

We are not out of the correction woods yet as mega-cap tech breaks below Friday's lows

Zacks Equity Research

BioNTech (BNTX) Begins Dosing in mRNA Cancer Vaccine Study

by Zacks Equity Research

BioNTech (BNTX) doses the first patient in a phase II study on its mRNA cancer vaccine candidate, BNT122, in patients with colorectal cancer.

Zacks Equity Research

3 Drugmakers in Focus After Merck's Positive COVID-19 Pill Data

by Zacks Equity Research

Here we discuss three other pharma or biotech companies with promising oral drug candidates for treating COVID-19 following Merck's (MRK) announcement of promising clinical data on its oral therapy.

Zacks Equity Research

Alcon's (ALC) Robust Product Line, Market Rebound Aid Growth

by Zacks Equity Research

In Presbyopia-correcting Intraocular Lens (PCIOLs), Alcon (ALC) currently leads the market with over 55% of global share and over 80% share in the United States.

Kinjel Shah headshot

Vaccine Stocks Down Following Merck's COVID-19 Pill Success

by Kinjel Shah

Stocks of several COVID-19 vaccine makers declined on Friday after Merck (MRK) released positive data for a new oral antiviral treatment for COVID-19

Zacks Equity Research

Gilead (GILD) Tecartus Gets FDA Nod for Leukemia Indication

by Zacks Equity Research

Following FDA approval, Gilead's (GILD) Tecartus becomes the first and only CAR T-cell therapy approved for treating relapsed/refractory B-cell acute lymphoblastic leukemia in adult patients.

Sweta Jaiswal, FRM headshot

Take a Look at the Top-Performing Biotech ETFs YTD

by Sweta Jaiswal, FRM

The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.

Zacks Equity Research

Bausch's (BHC) NOV03 for Dry Eye Disease Meets Study Goal

by Zacks Equity Research

Bausch Health (BHC) achieves study endpoints in the phase III study evaluating its investigational drug NOV03 in patients with DED associated with MGD.

Zacks Equity Research

Should First Trust NASDAQ100 Equal Weighted ETF (QQEW) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for QQEW

Zacks Equity Research

Pfizer's (PFE) Prevnar 20 Plus Flu Vaccine Study Meets Goal

by Zacks Equity Research

Pfizer's (PFE) Prevnar 20 co-administered with a flu vaccine elicits non-inferior immunogenicity compared to administration of the vaccines one month apart in a late-stage study.

Zacks Equity Research

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed at $378.90 in the latest trading session, marking a -1.38% move from the prior day.

Zacks Equity Research

Is Moderna (MRNA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (MRNA) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Ziopharm (ZIOP) Down on Workforce Reduction Announcement

by Zacks Equity Research

Ziopharm's (ZIOP) stock price falls after the announcement of several restructuring changes to advance the TCR program.

Zacks Equity Research

Pfizer (PFE) Submits COVID-19 Vaccine Data on Children to FDA

by Zacks Equity Research

Pfizer (PFE) and BioNTech plan to seek emergency use authorization for Comirnaty in children 5 to less than 12 years of age.

Zacks Equity Research

Sanofi (SNY) Ends mRNA COVID Vaccine Bid Despite Positive Data

by Zacks Equity Research

Sanofi (SNY) dumps development of mRNA-based COVID vaccine despite promising data from an early study. Instead, it will focus on its adjuvanted recombinant protein vaccine candidate.

Zacks Equity Research

Pfizer (PFE) Begins COVID Prevention, mRNA Flu Vaccine Studies

by Zacks Equity Research

Pfizer (PFE) begins new studies on its oral antiviral pill for the prevention of COVID-19 infection and a potential mRNA influenza vaccine.

Zacks Equity Research

Stock Market News for Sep 27, 2021

by Zacks Equity Research

After a roller coaster ride, the Dow and the S&P 500 closed in the green on Friday. However, China's move to ban cryptocurrencies weighed on the technology sector pushing the Nasdaq to close in the red.

Zacks Equity Research

AstraZeneca (AZN) Inks Deal to Enter Novel RNA Therapeutic Space

by Zacks Equity Research

AstraZeneca (AZN) inks a deal to gain the rights to the self-amplifying RNA platform developed by the Imperial College London.

Zacks Equity Research

Novavax (NVAX) Applies to WHO for COVID-19 Vaccine Listing

by Zacks Equity Research

On being granted the emergency use listing for Novavax's (NVAX) COVID-19 vaccine by WHO, it is to become eligible to supply the same to numerous countries participating through the COVAX facility

Zacks Equity Research

Pfizer (PFE) Booster Dose Gets CDC Backing for Older Adults Only

by Zacks Equity Research

The CDC recommends Pfizer (PFE)/ BioNTech's (BNTX) COVID-19 vaccine booster shots for older adults only but not for high-risk workers.

Sweta Jaiswal, FRM headshot

Will Pfizer ETFs Soar on FDA's COVID-19 Vaccine Booster Approval?

by Sweta Jaiswal, FRM

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging update in coronavirus vaccine.